Pinteon Therapeutics Information

View Top Employees from Pinteon Therapeutics

Pinteon Therapeutics is advancing clinical studies of a novel antibody that aims to interrupt the spread of toxic tau and protect and preserve brain function in patients with neurodegenerative disease. Pinteon’s lead asset, PNT001, is the only antibody in development that targets cis-pT231 tau, a neurotoxic epitope which has been identified in multiple preclinical studies as a potent driver of neurodegenerative disease. Pinteon is led by an experienced management team with strong track records in CNS drug discovery and development and is funded by Morningside Ventures. For more information, visit pinteon.com.

Website	http://www.pinteon.com
Revenue	$1 million
Employees	3 (0 on RocketReach)
Founded	2014
Address	1188 Centre St, Newton Center, Massachusetts 02459, US
Phone	+1 917-607-0015
Industry	Biotechnology Research, Business Services General, Health Care, Drug Delivery, Business Services, Medical, Pharmaceuticals, Therapeutics
Keywords	Neurodegenerative Diseases, Antibody Therapeutics, Clinical Trials, Drug Development, Alzheimers Treatment, Brain Health, Neurological Disorders, Biotechnology, Pharmaceutical Research, Precision Medicine, Immunotherapy, Protein Aggregation, Disease Treatment, Clinical Stage, Therapeutic Antibodies, Novel Therapeutics, Drug Discovery
Competitors	Novartis, Pfizer, Sanofi, AstraZeneca, Genentech, Amgen, Regeneron, Gilead Sciences, Biogen, Lilly India +44 more (view full list)
SIC	SIC Code 87 Companies, SIC Code 873 Companies
NAICS	NAICS Code 541714 Companies, NAICS Code 541 Companies, NAICS Code 5417 Companies, NAICS Code 54 Companies, NAICS Code 54171 Companies